OBX · Why this verdict
Why Obsidian Therapeutics (OBX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.2/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Obsidian Therapeutics is a speculative biotech down 70% from its high, where 124% analyst-target upside, rising estimates and a strong rebound rally compete with weak quality and an unprofitable profile.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Quality is 3.0/10, below the engine's 4.0 floor, with gross, operating and net margin components all at 0 and a Piotroski F-Score of only 4.4. Quality breakdown | Financial health should improve, lifting the Piotroski score above 6, within 12 months. | →Stable |
| CounterA pre-revenue biotech naturally shows zero margins, and a current ratio component of 7.9 indicates the balance sheet can fund operations for now. | ||
The $33.15 analyst target is 124.1% above the $14.79 price (164% raw analyst upside), for a reward-to-risk of 8.28 against 15.0% downside. Analyst target | The price should move substantially toward the target if clinical progress is confirmed. | ↓Deteriorating |
| CounterTargets for a binary-outcome biotech down 70% can be stale or based on trial success, and the target is more than double the current price. | ||
Earnings estimates have risen 5.6% over 30 days, giving the revision score of 8.5/10, and the latest report beat with a loss of $1.19 against $1.63 expected. Catalyst breakdown | Estimate revisions should stay positive over the next quarters. | ↓Deteriorating |
| CounterEarnings history is 2 beats and 2 misses and the beat reported rests on a loss estimate, so upward revisions may reflect lower expected losses rather than growth. | ||
Momentum is 7.3/10 with rising on-balance volume, but RSI is 70 after a 70% drawdown, which the engine labels an overbought bear rally. Momentum breakdown | Momentum should stay above 5.5 and the price should hold the rebound above its recent lows. | ↓Deteriorating |
| CounterThe 52-week position score is 0.0 and Bollinger is 1.1, so the stock is still near its lows and the rally could fade quickly. | ||
Quality is 3.0/10, below the engine's 4.0 floor, with gross, operating and net margin components all at 0 and a Piotroski F-Score of only 4.4.
→StableQuality breakdown
- Expectation
- Financial health should improve, lifting the Piotroski score above 6, within 12 months.
CounterA pre-revenue biotech naturally shows zero margins, and a current ratio component of 7.9 indicates the balance sheet can fund operations for now.
The $33.15 analyst target is 124.1% above the $14.79 price (164% raw analyst upside), for a reward-to-risk of 8.28 against 15.0% downside.
↓DeterioratingAnalyst target
- Expectation
- The price should move substantially toward the target if clinical progress is confirmed.
CounterTargets for a binary-outcome biotech down 70% can be stale or based on trial success, and the target is more than double the current price.
Earnings estimates have risen 5.6% over 30 days, giving the revision score of 8.5/10, and the latest report beat with a loss of $1.19 against $1.63 expected.
↓DeterioratingCatalyst breakdown
- Expectation
- Estimate revisions should stay positive over the next quarters.
CounterEarnings history is 2 beats and 2 misses and the beat reported rests on a loss estimate, so upward revisions may reflect lower expected losses rather than growth.
Momentum is 7.3/10 with rising on-balance volume, but RSI is 70 after a 70% drawdown, which the engine labels an overbought bear rally.
↓DeterioratingMomentum breakdown
- Expectation
- Momentum should stay above 5.5 and the price should hold the rebound above its recent lows.
CounterThe 52-week position score is 0.0 and Bollinger is 1.1, so the stock is still near its lows and the rally could fade quickly.
Per-dimension breakdown
Quality
3.0/10data confidence 86%| Component | Sub-score |
|---|---|
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 7.9 |
| Moat | 5.5 |
| Piotroski F | 4.4 |
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.5 |
| MACD | 0.0 |
| OBV | 1.0 |
| MA position | 2.5 |
| Volume | 10.0 |
| vol acceleration | 3.0 |
- ▸Volume distribution (falling OBV)
- ▸Volume surge (2.0x avg) on selloff
Sentiment
7.4/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 6.8 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (3.0) — signal dampened
- ▸Analyst upside: 306%
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
4.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.0 |
| growth rank | 5.0 |
Technical
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 10.0 |
| support resistance | 10.0 |
| 52w position | 0.0 |
Risk (lower is worse)
4.7/10data confidence 80%| Component | Sub-score |
|---|---|
| days to cover | 9.3 |
| volatility | 0.0 |
| beta | 0.0 |
| debt equity | 9.6 |
Catalyst
8.7/10data confidence 75%| Component | Sub-score |
|---|---|
| erm | 6.0 |
| earnings history | 10.0 |
| surprise avg | 10.0 |
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (6)
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:3.3<4.5
Warning (1)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
Reward-to-Risk
0.00
Upside
+62.0%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -81% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 3.3<4.5 outcome against Catalyst at 8.7 and asymmetric R:R of 0.00.
The strongest dimensions are Catalyst at 8.7, Sentiment at 7.4, and Insider at 7.3; the weakest are Quality at 3.0, Momentum at 3.3, and Risk (lower is worse) at 4.7. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Large Analyst Target Upside
Trip ifAnalyst target falls below $15.50 so that upside drops below 5% from 124.1%.
- P2Estimates Rising
Trip ifEarnings estimates fall more than 5% over 30 days, reversing the current +5.6%.
- P3Weak Quality No Margins
Trip ifPiotroski F-Score rises above 6 from the current 4.4.
- P4Bear Market Rally
Trip ifMomentum score falls below 4.5 from the current 7.3.